RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Harvard Bioscience Stock

Harvard Bioscience Net Income 2024

Harvard Bioscience Net Income

8.64 M USD

Ticker

HBIO

ISIN

US4169061052

WKN

578107

In 2024, Harvard Bioscience's profit amounted to 8.64 M USD, a -352.95% increase from the -3.42 M USD profit recorded in the previous year.

The Harvard Bioscience Net Income history

YEARNET INCOME (undefined USD)
2026e15.5
2025e12.63
2024e8.64
2023-3.42
2022-9.5
2021-0.3
2020-7.8
2019-4.7
2018-2.9
2017-0.9
2016-4.3
2015-19
20142.4
2013-1.8
20122.4
20113.8
201019
20097.2
20081.7
2007-1.4
2006-2.3
2005-31.9
20042.3

Harvard Bioscience Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Harvard Bioscience, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Harvard Bioscience from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Harvard Bioscience’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Harvard Bioscience. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Harvard Bioscience’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Harvard Bioscience’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Harvard Bioscience’s growth potential.

Harvard Bioscience Revenue, EBIT and net profit per share

DateHarvard Bioscience RevenueHarvard Bioscience EBITHarvard Bioscience Net Income
2026e140.76 M undefined23.36 M undefined15.5 M undefined
2025e126.53 M undefined13.67 M undefined12.63 M undefined
2024e114.19 M undefined12.55 M undefined8.64 M undefined
2023112.25 M undefined2.29 M undefined-3.42 M undefined
2022113.3 M undefined-4.7 M undefined-9.5 M undefined
2021118.9 M undefined3.4 M undefined-300,000 undefined
2020102.1 M undefined200,000 undefined-7.8 M undefined
2019116.2 M undefined2.8 M undefined-4.7 M undefined
2018120.8 M undefined4.8 M undefined-2.9 M undefined
201777.4 M undefined-600,000 undefined-900,000 undefined
2016104.5 M undefined-1.1 M undefined-4.3 M undefined
2015108.7 M undefined-900,000 undefined-19 M undefined
2014108.7 M undefined6.8 M undefined2.4 M undefined
2013105.2 M undefined3.7 M undefined-1.8 M undefined
2012111.2 M undefined8.1 M undefined2.4 M undefined
2011108.9 M undefined8.9 M undefined3.8 M undefined
2010108.2 M undefined10.7 M undefined19 M undefined
200985.8 M undefined8.6 M undefined7.2 M undefined
200888 M undefined10.1 M undefined1.7 M undefined
200783.4 M undefined9.5 M undefined-1.4 M undefined
200676.2 M undefined8.7 M undefined-2.3 M undefined
200567.4 M undefined7.9 M undefined-31.9 M undefined
200464.7 M undefined8.4 M undefined2.3 M undefined

Harvard Bioscience stock margins

The Harvard Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Harvard Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Harvard Bioscience.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Harvard Bioscience's sales revenue. A higher gross margin percentage indicates that the Harvard Bioscience retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Harvard Bioscience's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Harvard Bioscience's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Harvard Bioscience's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Harvard Bioscience. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Harvard Bioscience's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Harvard Bioscience Margin History

Harvard Bioscience Gross marginHarvard Bioscience Profit marginHarvard Bioscience EBIT marginHarvard Bioscience Profit margin
2026e59.15 %16.59 %11.01 %
2025e59.15 %10.8 %9.98 %
2024e59.15 %10.99 %7.56 %
202359.15 %2.04 %-3.04 %
202254.99 %-4.15 %-8.38 %
202156.94 %2.86 %-0.25 %
202056.81 %0.2 %-7.64 %
201955.51 %2.41 %-4.04 %
201855.46 %3.97 %-2.4 %
201750.65 %-0.78 %-1.16 %
201646.32 %-1.05 %-4.11 %
201544.8 %-0.83 %-17.48 %
201445.35 %6.26 %2.21 %
201345.34 %3.52 %-1.71 %
201247.03 %7.28 %2.16 %
201146.1 %8.17 %3.49 %
201047.87 %9.89 %17.56 %
200948.6 %10.02 %8.39 %
200847.95 %11.48 %1.93 %
200748.2 %11.39 %-1.68 %
200650 %11.42 %-3.02 %
200549.41 %11.72 %-47.33 %
200448.53 %12.98 %3.55 %

Harvard Bioscience Aktienanalyse

What does Harvard Bioscience do?

Harvard Bioscience Inc was founded in 1901 and is headquartered in Holliston, Massachusetts. The company is a global leader in providing instruments, technologies, and complete systems for science and research. Harvard Bioscience has established itself as one of the leading providers of products and solutions in the fields of life sciences and health research with over 100 years of industry experience. The business model of Harvard Bioscience is focused on delivering high-quality products and solutions for research needs. The company is divided into three business segments: Life Science Research Products, Preclinical Surgical Products, and Analytical Instruments. These business segments offer a variety of products, such as instruments for cell and molecular research, gene expression analysis devices, surgical instruments, and instruments for electrophysiology. The Life Science Research segment includes the business units Harvard Apparatus, Molecular Devices, and Denville Scientific. Harvard Apparatus provides instruments for cell and molecular research, physiological instruments, and animal model systems. Molecular Devices specializes in instrumental analysis methods for cell and molecular research. Denville Scientific is a leading supplier of products for cell and molecular biology, including materials for gene and protein expression and cell culture techniques. In the Preclinical Surgical Products segment, Harvard Bioscience operates with the company Hugo Sachs Elektronik. Surgical instruments and complete systems for preclinical research are offered here. These products are popular among scientists worldwide as they have been developed for conducting research with animal models. Analytical Instruments is the segment where the company operates joint ventures to develop instruments for physical, material, and life science research. In this segment, Harvard Bioscience is primarily involved in the joint venture Wasatch Microfluidics, alongside Agilent Technologies, which specializes in the development of instruments for life sciences and biotechnology. As a provider of science and research-related instruments and devices, Harvard Bioscience has a wide range of products to help researchers and scientists enhance their work more effectively. Some of the most popular products from Harvard Bioscience include tissue processing systems, neuroprotection applications, animal model holders, and electrophysiology platforms. Harvard Bioscience also offers a range of products for quality assurance and environmental protection, such as cleanroom and protection devices for material preparation and sterilization. Overall, Harvard Bioscience Inc has an excellent reputation in the industry and is one of the world's leading companies for scientific and research-related products and services. The company constantly strives to improve its products and services and adapts to the needs of its customers. It relies on innovation and continuously works to develop and implement new technologies to meet the demands of the scientific world. Harvard Bioscience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Harvard Bioscience's Profit Margins

The profit margins of Harvard Bioscience represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Harvard Bioscience's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Harvard Bioscience's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Harvard Bioscience's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Harvard Bioscience’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Harvard Bioscience stock

How much profit has Harvard Bioscience made this year?

Harvard Bioscience has made 8.64 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -352.95% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Harvard Bioscience publish its earnings?

Harvard Bioscience publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Harvard Bioscience?

The profits of Harvard Bioscience are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Harvard Bioscience?

You can learn more about the earnings of Harvard Bioscience by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Harvard Bioscience pay?

Over the past 12 months, Harvard Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Harvard Bioscience is expected to pay a dividend of 0 USD.

What is the dividend yield of Harvard Bioscience?

The current dividend yield of Harvard Bioscience is .

When does Harvard Bioscience pay dividends?

Harvard Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Harvard Bioscience?

Harvard Bioscience paid dividends every year for the past 0 years.

What is the dividend of Harvard Bioscience?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Harvard Bioscience located?

Harvard Bioscience is assigned to the 'Health' sector.

Wann musste ich die Aktien von Harvard Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Harvard Bioscience from 7/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/29/2024.

When did Harvard Bioscience pay the last dividend?

The last dividend was paid out on 7/29/2024.

What was the dividend of Harvard Bioscience in the year 2023?

In the year 2023, Harvard Bioscience distributed 0 USD as dividends.

In which currency does Harvard Bioscience pay out the dividend?

The dividends of Harvard Bioscience are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Harvard Bioscience stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Harvard Bioscience

Our stock analysis for Harvard Bioscience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Harvard Bioscience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.